LabCorp will develop and commercialize a blood-based molecular diagnostic test powered by NIS4 technology to help identify patients with at-risk nonalcoholic steatohepatitis.
Read More
The combined type 1 diabetes risk score approach incorporates genetics, clinical factors such as family history, and the count of islet autoantibodies.
Read More
Clinical laboratories are running more tests and a greater variety of tests than they were able to in recent months.
Read More
The discovery of two novel biomarkers—FKBPL and CD44—has the potential to change the way preeclampsia is managed.
Read More
Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease.
Read More